ImmunoPrecise Antibodies (IPATF) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) is a Canada-based contract research organization specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of preclinical research services, from target validation and lead identification through to humanization and optimization. Its capabilities encompass hybridoma, phage display, single B cell sorting and next-generation sequencing platforms to accelerate antibody candidate selection and characterization.

ImmunoPrecise serves biopharmaceutical and biotechnology partners worldwide, offering customized solutions for projects in immuno-oncology, infectious diseases, autoimmunity and other therapeutic areas. Services include in vitro and in vivo pharmacology studies, assay development, antibody engineering, and CMC support to help clients advance molecules toward clinical development. The company’s integrated approach aims to streamline discovery timelines and reduce development risks.

Founded in 2007 and headquartered in Victoria, British Columbia, ImmunoPrecise has expanded its global footprint with laboratories and offices in the United States, the United Kingdom and Germany. Through collaborations with academic institutions and industry leaders, the company leverages its multidisciplinary expertise to address complex research challenges and support the progression of novel biologics from concept to clinic.

Key Stats

• Today's Range: $1.37 to $1.50
• 50-Day Range: $1.18 to $1.85
• 52-Week Range: $1.15 to $20.25
• Volume: 445,607 shs
• Average Volume: 20,327 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IPATF
• CIK: N/A
• Web: www.immunoprecise.com
• Phone: (250) 483-0308
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A